Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3

被引：75

作者：

Boyd, Scott ^{[1
]}

Brookfield, Joanna L. ^{[2
]}

Critchlow, Susan E. ^{[1
]}

Cumming, Iain A. ^{[2
]}

Curtis, Nicola J. ^{[1
]}

Debreczeni, Judit ^{[1
]}

Degorce, Sebastien L. ^{[1
]}

Donald, Craig ^{[1
]}

Evans, Nicola J. ^{[3
]}

Groombridge, Sam ^{[1
]}

Hopcroft, Philip ^{[1
]}

Jones, Neil P. ^{[3
]}

Kettle, Jason G. ^{[1
]}

Lamont, Scott ^{[1
]}

Lewis, Hilary J. ^{[1
]}

MacFaull, Philip ^{[1
]}

McLoughlin, Sheila B. ^{[2
]}

Rigoreau, Laurent J. M. ^{[2
]}

Smith, James M. ^{[2
]}

St-Gallay, Steve ^{[1
]}

Stock, Julie K. ^{[3
]}

Turnbull, Andrew P. ^{[3
]}

Wheatley, Edward R. ^{[3
]}

Winter, Jon ^{[1
]}

Wingfield, Jonathan ^{[1
]}

机构：

[1] AstraZeneca, Oncol Innovat Med Unit, Macclesfield SK10 4TG, Cheshire, England

[2] CRT Discovery Labs, Cambridge CB22 3AT, England

[3] UCL, Wolfson Inst Biomed Res, CRT Discovery Labs, London WC1E 6BT, England

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 58卷 / 08期

关键词：

KEY GLYCOLYTIC ENZYME; 6-PHOSPHOFRUCTO-2-KINASE PFKFB3; CANCER; PHOSPHOFRUCTOKINASE; EXPRESSION; FAMILY;

D O I：

10.1021/acs.jmedchem.5b00352

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A weak screening hit with suboptimal physicochemical properties was optimized against PFKFB3 kinase using critical structure-guided insights. The resulting compounds demonstrated high selectivity over related PFKFB isoforms and modulation of the target in a cellular context. A selected example demonstrated exposure in animals following oral dosing. Examples from this series may serve as useful probes to understand the emerging biology of this metabolic target.

引用

页码：3611 / 3625

页数：15

共 50 条

[41] Strategies for the design of potent and selective kinase inhibitors
McInnes, C
Fischer, PM
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (14) : 1845 - 1863
[42] Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome
Momose, I
Umezawa, Y
Hirosawa, S
Iinuma, H
Ikeda, D
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (07) : 1867 - 1871
[43] Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design
Greenspan, PD
Clark, KL
Tommasi, RA
Cowen, SD
McQuire, LW
Farley, DL
van Duzer, JH
Goldberg, RL
Zhou, HH
Du, ZM
Fitt, JJ
Coppa, DE
Fang, Z
Macchia, W
Zhu, LJ
Capparelli, MP
Goldstein, R
Wigg, AM
Doughty, JR
Bohacek, RS
Knap, AK
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (26) : 4524 - 4534
[44] Structure-based design of cyclin-dependent kinase inhibitors
Davies, TG
Pratt, DJ
Endicott, JA
Johnson, LN
Noble, MEM
PHARMACOLOGY & THERAPEUTICS, 2002, 93 (2-3) : 125 - 133
[45] Identification of potent and novel phosphatidylinositol 3-Kinase catalytic subunit alpha inhibitors: a structure-based drug design approach
Madhukar, Geet
Subbarao, Naidu
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 : 28 - 29
[46] Structure-based design of a series of potent inhibitors of human f "-secretase
Vacca, Joseph P.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
[47] ITERATIVE STRUCTURE-BASED DESIGN OF POTENT, SYMMETRY BASED HIV PROTEASE INHIBITORS
RANDAD, RS
LUBKOWSKA, L
SILVA, A
BHAT, TN
GULNIK, S
YU, B
ERICKSON, JW
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 112 - MEDI
[48] Structure-based discovery and development of selective protein kinase inhibitors.
Rose, PE
Begley, M
Boucher, CE
Carney, D
Daniell, T
Kim, J
Morgenstern, K
Stover, D
Toledo, L
Zhao, H
Zhu, X
CLINICAL CANCER RESEARCH, 1999, 5 : 3753S - 3753S
[49] Structure-based design of selective calpain-2 inhibitors
Luo, Yun
Chatterjee, Payal
Alsamarah, Abdelaziz
Kent, David
Baudry, Michel
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[50] Structure-based drug design of selective 5′-nucleotidases inhibitors
Pachl, P.
Brynda, J.
Rosenberg, I.
Fabry, M.
Rezacova, P.
FEBS JOURNAL, 2009, 276 : 159 - 159

← 1 2 3 4 5 →